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Abstract
Background: Neglected tropical diseases are co-endemic in many areas of the world, including sub Saharan Africa. Currently
lymphatic filariasis (albendazole/ivermectin) and trachoma (azithromycin) are treated separately. Consequently, financial
and logistical benefit can be gained from integration of preventive chemotherapy programs in such areas.
Methodology/Findings: 4 villages in two co-endemic districts (Kolondièba and Bougouni) of Sikasso, Mali, were randomly
assigned to coadministered treatment (ivermectin/albendazole/azithromycin) or standard therapy (ivermectin/albendazole
with azithromycin 1 week later). These villages had previously undergone 4 annual MDA campaigns with ivermectin/
albendazole and 2 with azithromycin. One village was randomly assigned to each treatment arm in each district. There were
7515 eligible individuals in the 4 villages, 3011(40.1%) of whom participated in the study. No serious adverse events
occurred, and the majority of adverse events were mild in intensity (mainly headache, abdominal pain, diarrhoea and ‘‘other
signs/symptoms’’). The median time to the onset of the first event, of any type, was later (8 days) in the two standard
treatment villages than in the co-administration villages. Overall the number of subjects reporting any event was similar in
the co-administration group compared to the standard treatment group [18.7% (281/1501) vs. 15.8% (239/1510)]. However,
the event frequency was higher in the coadministration group (30.4%) than in the standard treatment group (11.0%) in
Kolondièba, while the opposite was observed in Bougouni (7.1% and 20.9% respectively). Additionally, the overall frequency
of adverse events in the co-administration group (18.7%) was comparable to or lower than published frequencies for
ivermectin+albendazole alone.
Conclusions: These data suggest that co-administration of ivermectin+albendazole and azithromycin is safe; however the
small number of villages studied and the large differences between them resulted in an inability to calculate a meaningful
overall estimate of the difference in adverse event rates between the regimens. Further work is therefore needed before co-
administration can be definitively recommended.
Trial Registration: ClinicalTrials.gov; NCT01586169
Citation: Coulibaly YI, Dicko I, Keita M, Keita MM, Doumbia M, et al. (2013) A Cluster Randomized Study of The Safety of Integrated Treatment of Trachoma and
Lymphatic Filariasis in Children and Adults in Sikasso, Mali. PLoS Negl Trop Dis 7(5): e2221. doi:10.1371/journal.pntd.0002221
Editor: Patrick J. Lammie, Centers for Disease Control and Prevention, United States of America
Received July 16, 2012; Accepted April 6, 2013; Published May 9, 2013
Copyright:  2013 Coulibaly et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study was funded in its entirety by a portion of grant number 37666 from the Bill & Melinda Gates Foundation (http://www.gatesfoundation.org)
to the International Trachoma Initiative. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: hedgepigs@aol.com
Introduction
Lymphatic filariasis (LF), a leading cause of permanent and long-
term disability globally, affects over 120 million people in more than
80 countries in tropical and subtropical areas [1]. Trachoma is the
main cause of infectious blindness, responsible for around 5% of the
world’s blind people [2]. These two infections represent important
public health problems in West Africa. Mali alone, with a
population of 14.5 million (2009), has approximately 300,000
people who are at risk of disability from these two diseases [3].
While the safety and efficacy of separate treatments for
trachoma and LF are well documented, their integrated treatment
still represents a global challenge. Azithromycin, an antibiotic, has
been used safely for over 10 years in trachoma treatment programs
[4,5]. The coadministration of single doses of two anti-parasitic
drugs, ivermectin and albendazole, is a standard and safe
treatment of LF in African countries where onchocerciasis is co-
endemic and has been shown to reduce transmission following
several rounds of MDA [6]. Ivermectin is indicated on its own for
the treatment of onchocerciasis and strongyloidiasis, and for LF in
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combination with albendazole [7]. Albendazole is indicated for soil
transmitted nematode infections and for systemic helminth
infections such as neurocysticercosis and echinococcosis. It is used
to treat LF in combination with ivermectin in areas co-endemic for
onchocerciasis and in combination with diethylcarbamazine in all
other LF-endemic areas. Both ivermectin and albendazole have an
excellent safety record when used alone and also, for the last 10
years, in combination [8,9].
Currently it is recommended that the administration of
azithromycin and ivermectin/albendazole be separated by 7 to
14 days in co-endemic areas [10,11], thus increasing the number
of subject contacts and therefore overall cost of the interventions.
It is therefore desirable to consider coadministration of drugs for
the two diseases if this can be shown to be safe. Integrating the
treatment of LF and trachoma would present logistical, health
(greater compliance through integration) and economic advantag-
es, helping reduce the burden on an already strained healthcare
system. Given the disabling consequences of untreated LF and
blinding trachoma, the large populations at risk for both diseases
and the resource constraints of the endemic countries, the
potential to improve the lives of the patients, optimize available
healthcare resources and maximize the number of people reached
make the minimal risks of initiating this new three-drug treatment
administration acceptable [12]. It is recognized that the current
approach is effective, safe, and free from SAE [8,9,13,14,15].
However, before integration can occur, the safety of coadminis-
tration of the three drugs (azithromycin, ivermectin and
albendazole) has to be examined.
The data to support such an approach is limited to a
pharmacokinetic study [16] on the interaction of the three drugs
(azithromycin, ivermectin and albendazole) conducted in the
United States in 18 healthy volunteers in 2004. Coadministration
resulted in an increase in systemic exposure (Cmax and AUC 0-t)
of azithromycin by 13% and 20% and in ivermectin exposure by
31% and 27% respectively. At the same time, albendazole
sulfoxide exposure was decreased by 16% and 14% respectively.
The changes in exposure to azithromycin and albendazole were
considered not to be of clinical importance, while the increase in
ivermectin exposure is of potential concern. Increased exposure to
ivermectin could potentially lead to high levels in the brain,
although a study in normal volunteers receiving 10 times the
current dose did not show significant CNS toxicity [17,18]. In this
small population of normal volunteers, increased ivermectin
exposure was not associated with an increased incidence of
adverse events, such as dizziness, typically associated with
ivermectin. One subject reported mild indigestion following
administration of the ivermectin/albendazole combination. The
other subject reported mild disequilibrium eight days after taking
the three drugs together. Neither of these events required
treatment. While these results are encouraging, they do not
eliminate the risk of pharmacodynamic interactions or effects in
infected patients.
Therefore given the outcome of the pharmacokinetic study in
healthy volunteers and the expected increased cost-effectiveness of
co-administration [12], the current pharmacovigilance study was
undertaken under the auspices of the International Trachoma
Initiative (ITI) with support from the Bill & Melinda Gates
Foundation and conducted by the Center for Disease Control of
Mali, to study the safety of coadministration of azithromycin,
ivermectin and albendazole for the mass treatment of trachoma
and LF in adults and children aged 5 and over in the Sikasso
region of Mali.
Materials and Methods
The study was an open label, community-based study compar-
ing the standard treatments for trachoma (single dose azithromy-
cin) and LF (ivermectin and albendazole) given 1 week apart with
the coadministration of the three drugs. The study was registered
with ClinicalTrials.gov with the reference NCT01586169.
Ethics Statement
The protocol was approved by the Ethics Committee of the
Faculty of Medicine, Pharmacy and Odontostomatology (FMPOS)
of the University of Bamako, and Malian Ministry of Health
through the National Directorate of Health and the Directorate of
Pharmacy and Drugs. Once the study sites had been identified, the
aim of the study and details of the procedures to be undertaken
were presented through the different levels of administration to the
level of the individual villages where meetings were held to provide
community understanding of the protocol. Once community
agreement had been obtained, a census of each village was
undertaken to identify households, families and individuals, each
of whom received a unique number. Subsequently, potential
subjects in the study provided their own written consent to
information provided on audiotape in Bambara (the local
language). Parents or guardians provided written consent for all
children participating in the study.
Study Site
Mali was chosen because trachoma and LF were co-endemic
and the baseline prevalence for both diseases from prior surveys
was relatively high. In addition, the infrastructure existed to allow
a study of this nature to be conducted.
In this study, the treatments were allocated to entire villages
(clusters). The decision to use a cluster design was taken for
logistical reasons. With the number of subjects involved, it would
be very difficult to implement individual randomisation within a
village. Furthermore, the study needed to assess the effects of mass
treatment in the community as that is the target setting for the
Author Summary
Neglected tropical diseases are co-endemic in many areas
of the world. Currently lymphatic filariasis (albendazole+i-
vermectin) and trachoma (azithromycin) are treated
separately. Benefits can be gained from integration of
preventive chemotherapy programs in such areas. To
assess the safety of this approach, 4 villages in two co-
endemic districts in Mali were randomly assigned to
coadministered treatment (ivermectin/albendazole/azith-
romycin) or standard therapy (ivermectin/albendazole with
azithromycin 1 week later). One village was randomly
assigned to each treatment in each district. 3011(40.1%) of
7515 eligible individuals in the 4 villages participated in
the study. No serious adverse events occurred, and most
events were mild in intensity (mainly headache, abdominal
pain, and diarrhoea). Overall the number of subjects
reporting any event was similar with co-administration
compared to standard treatment [18.7% (281/1501) vs.
15.8% (239/1510)]. The overall frequency of adverse events
with co-administration was comparable to or lower than
published frequencies for ivermectin/albendazole alone.
These data suggest that co-administration is safe; however
the small number of villages studied and the large
differences between them meant that a meaningful
estimate of the differences could not be calculated, and
further work will be needed before a recommendation can
be made.
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treatments under study. The villages chosen for the study needed
to be accessible, for logistical reasons, with access to a health
facility, but sufficiently far apart to avoid ‘‘contamination’’
between them. They had to be within 5 km of a serviceable road
and within 15 km of a Community Health Centre (CSCOM) at
the very peripheral level of the health system organization in Mali
or a district Reference Health Center (CSREF) that is responsible
for providing care to complicated cases referred from the different
CSCOMs of the district. Villages also needed to be separated by at
least 15 km and be on an East-West axis since the endemicity/
epidemiology of LF is more homogeneous than on a North-South
axis. They also needed to have populations of about 1200 people
of local ethnic groups with similar socio-cultural habits. The
anticipated exclusion rate was 25% so village populations needed
to be large enough to allow for 750 subjects to be recruited to the
study. Two districts, Bougouni and Kolondièba, in the Sikasso
region of southern Mali (Figure S1), were selected for the study.
Prior to study initiation, these districts had both received four
annual standard treatments with albendazole and ivermectin for
LF and two mass treatments with azithromycin for trachoma. It is
likely that these interventions had considerably reduced the
trachoma infection rate and filarial parasite load compared to
historical data for the area. For logistical reasons, the infection
rates were not re-evaluated immediately prior to the study
Trachoma is highly endemic in the Sikasso region and
preliminary results of surveys conducted by ITI in June 2008
(ITI unpublished data, 2008), overall prevalence of trachoma was
14.65% in Bougouni and 24.4% in Kolondièba, while the
prevalence in 1 to 9 year old children of the main stages of
trachoma, Trachoma Inflammation-Follicular (TF) and Tracho-
matous Inflammation-Intense (TI) in Bougouni and Kolondièba
were 5.8% (84/1456) and 7.5% (109/1453) respectively, a
substantial reduction from earlier surveys [19]. The prevalence
of LF in 2004 at before MDA was started was 19.8% in Bougouni
and 22.4% in Kolondièba (National LF Elimination Programme,
unpublished report). LF prevalence was not assessed in the study
villages prior to the study initiation but data from neighbouring
villages reported 14% and 24.4% respectively in the districts of
Bougouni (Mena, Tienkoungoba) and Kolondièba (Bougoula,
Kebila) (unpublished data, National LF Elimination Program,
Mali).
Based on the selection criteria above, two villages in each
district were chosen, Tienkoungoba (longitude 26.581690,
latitude 11.456120) [standard treatment] and Ména (longitude
26.812560, latitude 11.527540) [co-administered treatment] in
the District of Bougouni and the villages of Bougoula (longitude
27.094090, latitude 11.253810) [standard treatment] and Kebila
(longitude 27.041090, latitude 11.276370) [co-administered
treatment] in the District of Kolondièba. Allocation of treatment
in each district was decided by the toss of a coin by the
investigators following the investigators’ training session in
Bamako before the treatment phase field trip.
Study Personnel and Training
Prior to initiation of the field based phases of the study (census
and treatment/follow-up), the whole team was recruited and
underwent intensive training to ensure that every member knew
and understood their role. Since the treatment phase of the study
was to be conducted simultaneously in the 4 villages, the data
collection teams were all trained together on study methodology
and especially the use of the predetermined adverse event
questionaires. The details of the processes and the materials used
may be found in the Supplimentary file ‘Study Protocol’ Section 9
pages 32–35, and Appendices D through K.
Subjects
Following a complete census of the participating villages, all
residents were invited to attend for screening. Male and female
consenting/assenting subjects resident in the village for at least the
previous 3 months and aged between 5 and 65 years were
screened against inclusion criteria with a history and medical
examination, which included documentation of signs/symptoms of
trachoma (according to the WHO classification, and identified by
health technicians specialised in ophthalmology) and LF (elephan-
tiasis, lymphoedema, hydrocoele), prior to formal enrolment.
Enrolment continued until the target number of subjects,
approximately 40% of the total popualtion in each village, was
reached. Blood tests for microfilaraemia or antigenaemia were not
taken. All children over 5 years of age but under 90 cm in height
and all pregnant and lactating women were excluded. In addition,
all those who had significant acute or chronic illnesses or had a
history of allergy to the drugs to be given were excluded. Subjects
excluded after consent and non-enroled village residents were
offered treatment after the study using the standard regimens for
trachoma and LF according to national guidelines.
Treatment and Follow-up
Following consent and screening, all enrolled subjects within a
village received the drugs appropriate to the randomization.
Patients were identified after randomization since the whole village
was alocated to the same treatment. Subjects were aware of the
treatment they would receive during the consent process.
Appropriate doses for azithromycin and ivermectin were deter-
mined using a height pole marked with the doses on either side of
the pole (Table 1). In the standard treatment villages, all subjects
were treated on day 0, receiving ivermectin based on height (up to
463 mg tablets) and albendazole irrespective of height (16400 mg
tablet). They then received azithromycin based on height (up to
46250 mg tablets) 7 days later. In the coadministration villages, all
subjects received ivermectin based on height (up to 463 mg
tablets), albendazole irrespective of height (16400 mg tablet) and
azithromycin based on height (up to 46250 mg tablets) on day 1.
No treatment was given 7 days later. All treatment administration
was witnessed by study staff to ensure the medications were taken.
Study staff were not blinded to the treatment administration.
Subjects were seen and assessed on Days 1, 8 and 15. On Day 0,
in addition to a general examination, they were asked about any
complaints from a pre-specified list (e.g. abdominal pain,
headaches) or others (recorded verbatim) that existed prior to
treatment. On Days 8 and 15, the subjects underwent a further
clinical examination and were asked whether they had experi-
enced any AE since the administration of the drug, or whether any
complaints present prior to treatment had changed in any way.
Subjects were also able to present themselves at the health centres,
which were manned throughout the study, if they were concerned
about any events between the planned assessment visits. All AEs
were classified either as ‘minor’ (not interfering with daily function)
or ‘major’ (interfering with daily function). If AEs required
treatment, this was based on the presenting signs and symptoms.
Study investigators were located in village health centers or at
other appropriate sites recommended by villagers. Subjects went to
the agreed site to be assessed for eligibility for the study.
Households were grouped by sector and assigned investigators
with the aid of volunteers chosen by the villagers. These volunteers
also helped check that all households had been surveyed and
assisted in finding those who did not return for study assessments
on Days 8 and 15. Any subjects who had not returned for the Day
8 assessment by Day 14 were excluded from the study. Similarly,
Coadministered Treatment for Trachoma and LF
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any subjects not returning for the Day 15 assessment by Day 17
were excluded.
Statistical Methods
The study was designed to show that there was no difference in
the overall incidence of AE between the standard and coadmin-
istered treatment. Previous data on azithromycin suggested an AE
rate of 5% [20,21]. The incidence of AE with coadministered
treatment was estimated as 8%. With power of 80% and a two-
sided 95% confidence interval for the difference between rates, the
sample size chosen was 1125 subjects per treatment. The sample
size per group was increased to 1328 to allow for an 18% refusal
rate. This was in turn rounded up to 1500 per group to increase
the power. This required approximately 750 subjects per village in
order to produce clusters of equal size. The original sample size
calculations did not take into account that the study was based on
clusters (i.e., villages), where all subjects within the same cluster
received the same treatment and was thus grossly underpowered.
Analysis was therefore conducted at an individual, rather than a
cluster level.
The objective of the study was to assess safety of the three drugs
when coadministered. The primary outcome was therefore the
overall incidence of any AE. Any complaint, either one itemized in
a pre-prepared list in the case record form (CRF), or any other
untoward event occurring after treatment administration, or an
existing complaint which worsened after drug administration, was
considered as an AE. Each event was classified as minor (not
interfering with daily function), moderate (interfering to some
extent with daily function) or major (significant effect on daily
function). The timing of each event was derived as the first day on
which the event was recorded, calculated from the day of first drug
administration. The duration was also calculated as the number of
days from first appearance to last appearance (inclusive).
The incidence of each event itemized on the list in the CRF was
calculated by counting the number of subjects who reported it at
any time during the study. The incidence of any AE was derived in
Table 1. Dosing regimens for azithromycin, ivermectin and albendazole, according to height.
Participant height (cm) Azithromycin (250 mg tablets) Ivermectin (3 mg tablet) Albendazole (400 mg tablet)
Less than 90 None None None
90–94 1 tablet 1 tablet 1 tablet
95–119 2 tablets 1 tablet 1 tablet
120–123 2 tablets 2 tablets 1 tablet
124–140 3 tablets 2 tablets 1 tablet
141–143 3 tablets 3 tablets 1 tablet
144–158 4 tablets 3 tablets 1 tablet
More than 159 4 tablets 4 tablets 1 tablet
Note that at each height increment .90 cm the dosage of only 1 of the 3 medications changes (indicated in bold). Height was determined using a marked pole, with
separate graduations (one side for azithromycin and one for ivermectin). The sides were easily differentiated using words and symbols.
doi:10.1371/journal.pntd.0002221.t001
Table 2. Demographic summary for the study population in the 4 villages according to treatment.
BOUGOUNI KOLONDIÈBA
Standard Co-administered Standard Co-administered
n (%) n (%) n (%) n (%)
Sex
Female 373 (49.4%) 355 (47.3%) 360 (47.7%) 382 (50.9%)
Male 382 (50.6%) 395 (52.7%) 395 (52.3%) 369 (49.1%)
Age group
Under 10 254 (33.6%) 252 (33.6%) 236 (31.3%) 222 (29.6%)
10–19 281 (37.2%) 259 (34.5%) 291 (38.5%) 301 (40.1%)
20–29 33 (4.4%) 39 (5.2%) 53 (7.0%) 39 (5.2%)
30–39 36 (4.8%) 49 (6.5%) 33 (4.4%) 51 (6.8%)
40–49 53 (7.0%) 67 (8.9%) 69 (9.1%) 67 (8.9%)
50 and over 98 (13.0%) 84 (11.2%) 73 (9.7%) 71 (9.5%)
Not native
to village
3 (0.4%) 2 (0.3%) 25 (3.3%) 33 (4.4%)
Local 752 (99.6%) 748 (99.7%) 730 (96.7%) 718 (95.6%)
Total 755 (100.0%) 750 (100.0%) 755 (100.0%) 751 (100.0%)
doi:10.1371/journal.pntd.0002221.t002
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the same way, by counting the number of subjects reporting at
least one event, whether on the list or not, at some stage during the
study. Subjects reporting several events were only counted once.
The time to first onset for each subject was calculated as the day
on which the first AE of any kind occurred. The maximal severity
for each subject was calculated as the maximal severity of any
event reported during the study.
Since the study design did not fully account for the cluster
design, and since there were only two clusters for each treatment,
the scope for statistical analysis was limited. The overall incidence
of AE in each village was calculated as a simple percentage of the
total number of subjects who received treatment. A 95%
confidence interval was calculated using exact methods if
necessary (Wilson method, [22]). Note that even if there are no
Figure 1. Disposition of subjects.
doi:10.1371/journal.pntd.0002221.g001
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occurrences of a specific event in the study, the prevalence can still
be estimated with its 95% confidence interval. The time to first
onset of events in each village was investigated using survival
analysis methods. Data from any subject reporting no AE by the
end of the surveillance period was considered to be censored at the
time of last assessment. The analysis was repeated for those
subjects who experienced any AE and the median time to first
onset was estimated with its 95% confidence interval. The
severities of events were summarized in a table.
The frequency of occurrence of each event itemized in the CRF
was summarized for each treatment within each district in tables
and bar charts showing the percentage of the study population
within the village who reported the event. The incidence of each
type of event for each village was also shown with associated 95%
confidence intervals graphically, with a separate plot for each type
of event. The time to onset of the most frequently occurring events
was also investigated using survival analysis methods.
The age-sex distribution of the study population within each
village was compared to the overall village population using
graphs.
The intra-class correlation coefficient and associated 95%
confidence interval was calculated using the ANOVA estimator
[23]. Due to the small number of clusters, the resulting estimate
should be treated with caution.
Results
Study Population
There were 9109 persons in the villages in the two districts of
whom 7515 were eligible for inclusion (aged between 5 and 65
years, inclusive). 3011 subjects were chosen at random from this
pool to be included in the study population (Table 2), selection
continuing until the target number in a village was reached, with
1510 receiving the standard treatment (755 in each district) and
1501 receiving the coadministered treatment (750 in Bougouni,
751 in Kolondièba) (Figure 1). Recruitment of subjects started on
February 7, 2010 with the first treatment being administered the
same day while the final subject assessment was done on February
26, 2010. The recruitment took 3 to 4 days per village and all the
villages began the recruitment on the same day
Table 3. Complaints recorded prior to treatment (Day 0).
BOUGOUNI KOLONDIÈBA
Standard Co-administered Standard Co-administered
n (%) n (%) n (%) n (%)
Total number of subjects 755 (100.0%) 750 (100.0%) 755 (100.0%) 751 (100.0%)
Any complaint 354 (46.9%) 263 (35.1%) 198 (26.2%) 331 (44.1%)
Headaches 99 (13.1%) 71 (9.5%) 63 (8.3%) 115 (15.3%)
Fever 10 (1.3%) 1 (0.1%) 10 (1.3%) 17 (2.3%)
Tinnitus 4 (0.5%) 2 (0.3%) 8 (1.1%) 3 (0.4%)
Deafness 6 (0.8%) 5 (0.7%) 5 (0.7%) 0 (0.0%)
Jaundice 0 (0.0%) 2 (0.3%) 0 (0.0%) 0 (0.0%)
Weakness 1 (0.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Fatigue 10 (1.3%) 15 (2.0%) 2 (0.3%) 8 (1.1%)
Nausea 6 (0.8%) 8 (1.1%) 10 (1.3%) 4 (0.5%)
Vomiting 3 (0.4%) 1 (0.1%) 0 (0.0%) 3 (0.4%)
Diarrhea 4 (0.5%) 1 (0.1%) 1 (0.1%) 2 (0.3%)
Abdominal pain 75 (9.9%) 37 (4.9%) 43 (5.7%) 84 (11.2%)
Flatulence/dyspepsia 9 (1.2%) 16 (2.1%) 9 (1.2%) 4 (0.5%)
Constipation 22 (2.9%) 6 (0.8%) 9 (1.2%) 6 (0.8%)
Joint/muscular pain 47 (6.2%) 44 (5.9%) 24 (3.2%) 23 (3.1%)
Swelling of (upper/lower) limbs 0 (0.0%) 0 (0.0%) 1 (0.1%) 0 (0.0%)
Swelling of eyelids/abnormal
feeling in eyes
2 (0.3%) 6 (0.8%) 22 (2.9%) 6 (0.8%)
Rash/plaque 0 (0.0%) 1 (0.1%) 0 (0.0%) 0 (0.0%)
Scrotal reaction 1 (0.1%) 0 (0.0%) 1 (0.1%) 0 (0.0%)
Skin nodules 0 (0.0%) 3 (0.4%) 0 (0.0%) 1 (0.1%)
Worm expulsion 1 (0.1%) 25 (3.3%) 6 (0.8%) 2 (0.3%)
Haematuria 28 (3.7%) 4 (0.5%) 0 (0.0%) 3 (0.4%)
Adenopathy 1 (0.1%) 1 (0.1%) 0 (0.0%) 0 (0.0%)
Palpitation/tachycardia 5 (0.7%) 4 (0.5%) 3 (0.4%) 4 (0.5%)
Orthostatic hypotension 0 (0.0%) 3 (0.4%) 0 (0.0%) 1 (0.1%)
Other 145 (19.2%) 100 (13.3%) 57 (7.5%) 194 (25.8%)
doi:10.1371/journal.pntd.0002221.t003
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The male to female ratio was approximately equal in all villages
(Table 2). In all villages, the proportion of males included in the
study was slightly higher than the overall proportion of males in
the village, with the proportion of females being correspondingly
lower. The village allocated the coadministered treatment in the
Kolondièba district (Kebila) was larger than the rest, hence the
study population formed a smaller proportion of the total village
population.
The age distribution of the study population in each village was
similar (Table 2), with approximately 70% aged under 19 years
and 10.8% aged over 50 years which represents the age structure
within the villages as a whole. The age ranged from 5 to 65 years
in all villages, with a mean of 20 years and a median of 12 years
(Bougouni) or 13 years (Kolondièba).
The majority of study subjects were from the treatment villages
(Table 2). The proportion of outsiders recruited to the study in
Kolondièba was slightly higher (3.9%) than in Bougouni (0.3%),
although the majority came from neighbouring villages and had
been domiciled in the treatment villages for at least 3 months.
None came from non-endemic areas. The height and weight
distributions were similar for the four villages.
Slightly less than 5% of the total study population were found to
have signs of trachoma. Two of the villages (Bougouni standard and
Kolondièba coadministered treatment) had low rates of trachoma
(0.9% and 1.9%) while the other two (Bougouni coadministered and
Kolondièba standard treatment) had higher rates (6.0% and 8.7%).
For these latter two villages the most frequent types of trachoma
were follicular and scarring trachoma (eyelid scarring). 12 of the 14
subjects in Kebila (Kolondièba, coadministered treatment) had
follicular trachoma. No subject in any of the villages had corneal
opacity. Other findings from the eye examination were seen for
between 0.8% (Kolondièba, coadministered treatment) and 5.9%
(Bougouni, coadministered treatment). The pattern was similar as
seen for the overall incidence of trachoma, with a lower level of
other findings for Bougouni standard and Kolondièba coadminis-
tered treatment (less than 3% of subjects) and higher levels for
Figure 2. Complaints at baseline. Graph shows the incidence of specific complaints reported by 1% or more of subjects at baseline. Percentages
are calculated using the total number of study subjects in each village. ‘‘Other’’ comprises any complaints not listed in the Case Report Form.
doi:10.1371/journal.pntd.0002221.g002
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Bougouni coadministered and Kolondièba standard treatment
(above 4%). The most frequently occurring findings were chronic
tropical endemic limboconjunctivitis (TELC), cataract, pterygium
and conjunctivitis.
The number of abnormal findings from the LF examination was
very low: 12 subjects with hydrocoele (6 on each treatment). One
subject (Kolondièba, coadministered treatment) had both hydro-
coele and lymphoedema: this was the only subject to have
lymphoedema.
Treatment Dosing and Compliance
The number of tablets administered was almost always correct
according to height. There were more dosing errors for
azithromycin than for ivermectin. There was a slightly higher
error rate for the administration of the coadministered drugs than
for the standard treatment: 13 subjects (0.9%) and 27 subjects
(1.8%) had incorrect numbers of ivermectin and azithromycin
tablets respectively in the coadministered groups compared to 3
(0.2%) and 12 (0.8%) for the standard treatments.
There were two instances of regurgitation of drugs on Day 0,
both with the coadministered treatment. There were also two cases
on Day 8 (azithromycin only). The drugs were not taken again in
only one case. The majority, at least 95%, of subjects in all villages
except Kebila (Kolondièba, coadministered treatment) took their
drugs after a meal: in Kebila, only 577 subjects (76.8%) took their
drugs after a meal. On Day 8, all the subjects with data recorded
took their medication (azithromycin only) after a meal; 2 subjects
had no data on time of drug intake recorded.
There were no losses to follow-up, all subjects allocated to
treatment being evaluated within the timelines established for the
protocol.
Complaints Prior to Treatment
Table 3 summarizes the prevalence of complaints reported prior
to treatment administration, with the most frequently occurring
shown in Figure 2. The prevalence ranged from 26.2% (Kolon-
dièba, standard treatment) to 46.9% (Bougouni, standard treat-
ment). The most frequently reported of the complaints named in the
CRF were headaches (348 subjects, 162 on standard treatment, 186
on coadministered treatment) with prevalence ranging from 8.3%
(Kolondièba, standard treatment) to 15.3% (Kolondièba, coadmin-
istered treatment), and abdominal pain (239 subjects, 118 on
standard treatment, 121 on coadministered treatment), with
prevalences ranging from 4.9% (Bougouni, coadministered treat-
ment) to 11.2% (Kolondièba, coadministered treatment).
However, there were more subjects with pre-existing complaints
classified as ‘‘Other’’: 496 subjects (202 on standard treatment,
294 on coadministered treatment). The frequency of these varied
widely between the villages: 57 subjects (7.5%) in Bougoula
(Kolondièba, standard treatment), 100 subjects (13.3%) in Ména
(Bougouni, coadministered treatment), 145 subjects (19.2%) in
Tienkoungoba (Bougouni, standard treatment) and 194 subjects
(25.8%) in Kebila (Kolondièba, coadministered treatment). The
most commonly reported were cough (all villages except for
Bougoula), lower back pain (Kolondièba, both villages), epigas-
tralgia (Bougouni, both villages) and various other types of pain.
Table 4. Adverse event summary for the population according to district and d treatment.
BOUGOUNI KOLONDIÈBA
Standard Co-administered Standard Co-administered
n (%) n (%) n (%) n (%)
Any AEs
No 597 (79.1%) 697 (92.9%) 672 (89.0%) 523 (69.6%)




None 598 (79.2%) 697 (92.9%) 673 (89.1%) 523 (69.6%)
1 or more 157 (20.8%) 53 (7.1%) 82 (10.9%) 228 (30.4%)
Any exacerbated
complaints
None 746 (98.8%) 748 (99.7%) 749 (99.2%) 746 (99.3%)
1 or more 9 (1.2%) 2 (0.3%) 6 (0.8%) 5 (0.7%)
Maximal severity1
None 598 (79.2%) 697 (92.9%) 673 (89.1%) 523 (69.6%)
Minor 90 (11.9%) 20 (2.7%) 47 (6.2%) 197 (26.2%)
Moderate 61 (8.1%) 32 (4.3%) 33 (4.4%) 28 (3.7%)
Major 6 (0.8%) 1 (0.1%) 2 (0.3%) 3 (0.4%)
No. of AEs recorded
None 597 (79.1%) 697 (92.9%) 672 (89.0%) 523 (69.6%)
1 105 (13.9%) 29 (3.9%) 55 (7.3%) 168 (22.4%)
2 41 (5.4%) 19 (2.5%) 18 (2.4%) 47 (6.3%)
3 or more 12 (1.6%) 5 (0.7%) 10 (1.3%) 13 (1.7%)
1Calculated for each subject as maximal severity of all events reported; thus data is not available where exacerbated complaints were not recorded as AEs.
doi:10.1371/journal.pntd.0002221.t004
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Adverse Events
Table 4 summarizes the overall incidence of AE. The incidence
of events in each village with its 95% confidence interval is also
summarized in Figure 3.
The confidence intervals are all narrow due to the large sample
size in each village, and there is no overlap between the four. The
difference between treatment regimens differs between the
districts, with a higher incidence for the coadministered treatment
than the standard treatment in Kolondièba (30.4% vs. 11.0%), but
a lower incidence in Bougouni (7.1% vs. 20.9%). Due to the clear
differences between the incidences of AE in each village, formal
statistical comparison between the two treatments is not appro-
priate. The intra-class correlation coefficient (ICC) was estimated
to be 0.069 (95% CI: 0 to 0.174).
No serious adverse events were reported following treatment.
Twelve subjects (8 out of 241 with any AE on standard treatment
and 4 out of 281 on coadministered treatment) reported events of
major severity. Where necessary, subjects were treated symptom-
atically, most requiring paracetamol for pain or headache.
Most subjects only experienced one type of AE: 66.4% (160/
241) of subjects reported an AE with the standard treatment and
70.1% (197/281) with the coadministered treatment. Fewer than
2% of all subjects in each village reported 3 or more events. Of
those subjects who did report an AE, 7.6% and 12.0% in the
control villages and 9.4% and 5.7% in the coadministration
villages reported 3 or more. One subject (Bougouni, standard
treatment) had seven types of AE recorded.
Overall, there was no difference in AE rates according to
whether there were pre-existing complaints reported.
In most cases, pre-existing complaints had either disappeared or
improved by Day 8. Some were ongoing, and a small number still
continued up to Day 15. At the Day 8 assessment, a small number
of complaints were reported as worse after treatment: these were
mainly headaches (7 subjects) and abdominal pain (6 subjects).
There was also one case each of fever, joint pain and deafness,
which were exacerbated by treatment. At the final (Day 15)
assessment, only one subject reported an exacerbation of a pre-
existing complaint. This was a case of abdominal pain in the
standard treatment (Kolondièba).
All but one of the headaches exacerbated by treatment were
reported as AEs. Of the six subjects with abdominal pain, four were
reported as an AE, two were not. The case of worsened fever was
not reported as an AE, nor was the exacerbated deafness. There was
one case of exacerbated joint pain that was reported as an AE.
Table 5 shows the frequency of each individual type of event as
listed in the CRF. The data is summarized graphically for the most
frequent events in Figure 4. Abdominal pain, headaches, diarrhea
and events other than those itemized in the CRF were the most
common types of event in all villages. The incidence of each of the
main events with 95% confidence intervals is summarized for each
village in Figure 5.
Overall, and in three of the four villages, the most frequently
reported event was abdominal pain, with rates ranging from 2.1%
(Bougouni, coadministered treatment) to 17.2% (Kolondièba,
Figure 3. Overall incidences of adverse events. Graph shows the overall incidence of adverse events in each village, calculated as the
percentage of subjects in each village who reported at least one adverse event at any time after treatment, with associated 95% confidence intervals.
doi:10.1371/journal.pntd.0002221.g003
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coadministered treatment) which was considerably higher than in
any of the other three villages (Figures 4 and 5). The exception was
Tienkoungoba (Bougouni, standard treatment), where more people
experienced headaches (55 subjects, 7.3%) or other types of event
(56 subjects, 7.4%). The incidence of diarrhea was slightly higher in
the coadministered treatment village in Kolondièba than in the
other three villages (6.7% compared to rates below 3%). The
incidence of joint or muscular pain was similar in all four villages.
The only other events reported by more than 1% of the study
population in any of the villages were vomiting (2.8% Kolondièba,
coadministered treatment), nausea (2.0% Kolondièba, coadminis-
tered treatment) and fever (1.2%, Bougouni, standard treatment).
Of these, the only event for which the upper limit of the
confidence interval exceeded 4% was vomiting (Kolondièba,
coadministered treatment, upper 95% confidence limit = 4.2%).
The upper 95% confidence limit for the prevalence of events
specified in the CRF but which were not experienced by any
subjects in the study is 0.5%. With the exception of nausea and
vomiting, the incidences of all other AE types specified in the CRF
are comparable between the villages, with overlapping confidence
intervals.
Of the five subjects who had pre-existing complaints exacer-
bated which were not recorded as AE, two reported worsened
abdominal pain, and one each reported heightened fever,
headache and exacerbated deafness.
Of the 12 subjects with AE classified as major, 8 received standard
treatment (6 in Bougouni district, 2 in Kolondièba) and 4 received
coadministered treatment (1 in Bougouni district, 3 in Kolondièba).
The distribution of events and their nature is shown in Table 6.
There was no clear pattern to the types of event reported as
‘‘Other’’. In Tienkoungoba (standard treatment, Bougouni), the
most common events were respiratory in nature (18 cases,
comprising coughs and rhinitis), and vertigo (15 cases). In Bougoula
(standard treatment, Kolondièba) where the event rate was lower,
vertigo was the most commonly reported ‘‘Other’’ event (6 cases). In
Kebila (coadministered treatment, Kolondièba), the most common
events were somnolence (26 cases) and vertigo (9 cases). The most
frequent type of ‘‘Other’’ event in Mena (coadministered treatment,
Bougouni) was epigastralgia, reported by 3 subjects.
There is a clear difference between the villages in time to onset
of events, with most of the events occurring immediately after
treatment in Kebila (Kolondièba, coadministered treatment,
Figure 6). There is also evidence that the event rate increased
on day 8 with the administration of azithromycin in the standard
treatment villages.
The median time to the onset of the first event, of any type,
calculated from all those with any event, is 8 days for the two
standard treatment villages compared to 2 days and 0 days for the
coadministered treatment villages in Bougouni and Kolondièba
respectively.
Table 5. Type of adverse event encountered according to district and treatment received.
BOUGOUNI KOLONDIÈBA
Standard Co-administered Standard Co-administered
n (%) n (%) n (%) n (%)
Abdominal pain 48 (6.4%) 16 (2.1%) 22 (2.9%) 129 (17.2%)
Headaches 55 (7.3%) 14 (1.9%) 22 (2.9%) 26 (3.5%)
Diarrhea 16 (2.1%) 13 (1.7%) 20 (2.6%) 50 (6.7%)
Joint/muscular pain 15 (2.0%) 7 (0.9%) 11 (1.5%) 5 (0.7%)
Vomiting 6 (0.8%) 3 (0.4%) 4 (0.5%) 21 (2.8%)
Nausea 6 (0.8%) 2 (0.3%) 7 (0.9%) 15 (2.0%)
Fever 9 (1.2%) 3 (0.4%) 3 (0.4%) 2 (0.3%)
Weakness 5 (0.7%) 5 (0.7%) 1 (0.1%) 6 (0.8%)
Constipation 4 (0.5%) 3 (0.4%) 2 (0.3%) 2 (0.3%)
Flatulence/dyspepsia 2 (0.3%) 4 (0.5%) 2 (0.3%) 2 (0.3%)
Swelling of eyelids/abnormal feeling
in eyes
0 1 (0.1%) 4 (0.5%) 2 (0.3%)
Fatigue 1 (0.1%) 1 (0.1%) 1 (0.1%) 3 (0.4%)
Tinnitus 3 (0.4%) 0 1 (0.1%) 0
Palpitation/tachycardia 1 (0.1%) 1 (0.1%) 0 1 (0.1%)
Haematuria 0 2 (0.3%) 0 0
Rash/plaque 0 0 0 2 (0.3%)
Swelling of (upper/lower) limbs 0 0 1 (0.1%) 1 (0.1%)
Adenopathy 0 0 1 (0.1%) 0
Deafness 0 0 1 (0.1%) 0
Orthostatic hypotension 0 0 1 (0.1%) 0
Scrotal reaction 0 0 0 1 (0.1%)
Worm expulsion 1 (0.1%) 0 0 0
Other 56 (7.4%) 11 (1.5%) 20 (2.6%) 35 (4.7%)
Percentages for incidence of each event are calculated using the numberof treated subjects in each village.
doi:10.1371/journal.pntd.0002221.t005
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For the five most common types of event, namely, headaches,
abdominal pain, diarrhea, joint/muscular pain and other non-
specified events, a similar pattern in terms of time to onset was
seen. This was most marked for abdominal pain: in Kebila
(Kolondièba, coadministered treatment), almost all cases of
abdominal pain first occurred on the day of drug administration.
For diarrhea and events not specified in CRF, however, the time
to onset was most rapid in the Kolondièba coadministered
treatment village. The median time to onset of events with the
standard treatment was always Day 8, coinciding with the
administration of azithromycin. It is clear from the graphs that
onset was quickest with the coadministered treatment in
Kolondièba, with most events being reported as starting on the
day of treatment administration. Duration of adverse events
(number of days from first to last reporting of an event) is
summarized in Figure S2
Discussion
The aim of the study was to demonstrate that the prevalence of
AE after administering ivermectin, albendazole and azithromycin
simultanously was similar to the standard regimen where
azithromycin is given one week after the coadminstration of
ivermectin and albendazole. A similar approach to the establish-
ment of safety of three drug combinations was taken for
albendazole/ivermectin/praziquantel with a pharmacokinetic
study [24] followed by clinical safety evaluation [25]. The study
was designed as a cluster randomized study, with two villages in
each of two districts in Mali being randomized to one of the two
regimens; all enrolled subjects in each village received the
treatment as determined for that village. Since only four clusters
(villages) were studied, it is difficult to determine whether the clear
differences in AE between clusters (villages) were due to treatment
Figure 4. Incidence of most common adverse events. Graph shows the incidence of the most commonly reported types of event overall.
Percentages are calculated using the total number of treated subjects in each village. ‘‘Other’’ comprises any events not listed in the Case Report
Form.
doi:10.1371/journal.pntd.0002221.g004
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or to other factors. This is a major limitation of the study that the
villages as the clusters consitute the main units of analysis, a fact
that was not appreciated when the study was designed. The high
ICC (0.069) suggests that the study was under-powered and that
ideally many more smaller clusters should have been studied;
however, this would have imposed considerable logistical problems
and may not have been feasible in the current setting. In
retrospect, the study design chosen was inappropriate, and found
to be underpowered, which emphasises the need for statistical
input when considering alternative approaches.
No serious adverse events were reported, and adverse events
that were reported were generally mild or moderate.
The uptake of treatment was good in all four villages and all
subjects were followed-up for the requisite time. Administration of
drugs was almost always after a meal, except for the coadminis-
tered treatment in Kebila (Kolondièba), where a quarter of
subjects took their medication on an empty stomach. Incorrect
dose by height was rare in all villages with errors made in less than
2% of subjects
There was a marked difference in AE rates seen between the
villages. The event rate was 20% or above in the village allocated
standard treatment in Bougouni and the village allocated
coadministered treatment group in Kolondièba. Conversely, the
rates in the other two villages were 11% or below and were close to
the projected rates of 5% and 8% for standard treatment and
coadministered treatment respectively. The difference could be
partly attributable to the two villages with the higher AE rates
being more developed with a better educated population who were
Figure 5. Most common adverse events. Graph shows the incidence of the most commonly reported types of event overall, with 95%
confidence intervals. Percentages are calculated using the total number of treated subjects in each village. ‘‘Other’’ comprises any events not listed in
the Case Report Form.
doi:10.1371/journal.pntd.0002221.g005
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more likely to report AE. Both of these villages were situated on a
main road with better access to services and other infrastructure.
The other two villages were less developed and in more rural
locations. There did not appear to be any relationship between the
incidence of AE and the presence of pre-existing complaints, since
within each village, the prevalence of experiencing any AE was
similar for those with and without complaints at baseline.
Nevertheless, the two villages with the highest AE rates also had
the highest prevalence of pre-existing complaints (44.1% and
46.9%). This provides further support to the underlying difference
between the villages in terms of their attitude to health. Although a
potential source of bias, there is no evidence that the differing
Table 6. Major adverse events reported post treatment.
BOUGOUNI KOLONDIÈBA
Standard Co-administration Standard Co-administration
n n n n











1Exacerbation of pre-existing complaint.
2Onset occurred on Day 7 for one subject and Day1 for the other. Neither subject had any abnormal findings from the eye examination, although one subject did report
‘‘Watering (larmoiement)’’ before treatment.
doi:10.1371/journal.pntd.0002221.t006
Figure 6. Time to onset of adverse events. The graph shows the estimated proportion of treated subjects in each village on each study day who
had reported at least one adverse event from the time of receiving the study medication. The band represents the 95% confidence region for the
estimates. Estimates were derived using survival analysis methods.
doi:10.1371/journal.pntd.0002221.g006
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frequencies of AEs was the result of treatment seeking behaviour
within the communities.
The onset of events with coadministered treatment in
Kolondièba was extremely rapid with nearly all events, the most
frequent being abdominal pain (16.1%), occurring on the day of
administration. The incidence of diarrhea was also higher than in
other villages. All other events were reported by fewer than 5% of
the study population in that village. Adverse events in the standard
treatment villages generally occurred when azithromycin was
given on Day 8. This was especially noticeable for gastrointestinal
events such as abdominal pain and diarrhea.
All events other than the most common (abdominal pain,
headaches, diarrhea, joint or muscular pain, and ‘other’ non-
specified events) were seen in less than 1% of the study population in
all villages. The exceptions were vomiting (2.8%) and nausea (2%) in
the coadministered treatment village in Kolondièba and fever (1.2%)
in the standard treatment village in Bougouni. Events described as
‘‘Other’’ were most commonly respiratory symptoms, vertigo, or
somnolence. There was no clear pattern associated with treatment.
Although examinations were conducted to record the presence
of symptoms and signs of trachoma and LF, no tests (antigen test
or night blood for microfilaria) were conducted to demonstrate
asymptomatic infection with lymphatic filariasis. Clearance of
microfilaraemia following treatment with ivermectin and alben-
dazole may lead to symptoms such as myalgia and joint pains, but
the incidence of such symptoms in the treated population as a
whole was low [8]. This, coupled with the relative rarity of clinical
evidence (hydrocele or lymphoedema), suggests that the National
Lymphatic Filariasis Elimination Programme has made excellent
progress towards controlling the disease in the study areas as a
result of 5 rounds of annual MDA prior to the study. In the case of
trachoma, elimination of Chlamydia trachomatis in an individual
would not be expected to cause AE. The lack of significant levels of
clinical disease may, however, have led to a lower than expected
AE rate, especially with respect to those events typically associated
with treatment of microfilaraemia.
Another limitation of the study is that treatment allocation was
not blinded to the investigators, potentially resulting in observer
bias in the assessment of AE. Furthermore, subjects were aware of
their treatment regimen. As part of the study protocol, the cost of
treating AE was met by the sponsor, which may also have
influenced subjects to over-report events in order to access medical
services. The analysis took no account of family or household
groupings, which may also have a bearing on AE reporting.
However, given the limitations imposed by the design, and the
large discrepancy between AE rates in the four villages, this was
not felt to be a major omission.
While the study design does not permit a statistical conclusion to
be made, the pattern and timing of events does suggest that most
AE are associated with administration of azithromycin, and that
coadministration of all three drugs does not increase the frequency
or severity of AE in this setting.
Conclusions
The design of the study with a small number of large clusters
means that comparisons of the overall AE rates for the two
treatment regimens are difficult to make since there were only two
villages receiving each treatment, and the AE rates differed
markedly between villages. Nevertheless, there is no clear evidence
to suggest that the coadministered treatment is associated with a
higher rate of AE than the standard treatment. The types of event
occurring most frequently were similar for all four villages, and the
events reported, especially abdominal pain and diarrhoea were
temporally accociated with azithomycin administration as expect-
ed. The study demonstrated that it is feasible to administer the
three drugs together, which would significantly reduce the
logistical demands on conducting mass treatment of LF and
trachoma in this setting.
However, given the limitations of the current study, further
investigation would be desirable. Any new study will need to
consider the design issues raised here, and especially whether a
cluster randomised approach is appropriate. Furthermore, the
studies need to be conducted in areas where there is an
appreciable prevalence of LF to determine whether coadminis-
tered treatment increases the incidence of AEs associated with
microfilaraemia.
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